Notice: This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends Get the Latest News and Ratings for BOLD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Audentes Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up BOLD Analyst Ratings Over TimeTypeCurrent Forecast11/3/23 to 11/2/241 Month Ago10/4/23 to 10/3/243 Months Ago8/5/23 to 8/4/241 Year Ago11/3/22 to 11/3/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s) N/A Buy3 Buy rating(s)3 Buy rating(s)3 Buy rating(s) N/A Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s) N/A Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s) N/A Consensus Price Target$23.00$23.00$23.00N/AForecasted Upside671.81% Upside634.82% Upside623.27% UpsideN/AConsensus RatingBuyBuyBuyN/A 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here BOLD Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BOLD Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Audentes Therapeutics Stock vs. The CompetitionTypeAudentes TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 3.00 2.79 2.50Consensus RatingBuyModerate BuyHoldPredicted Upside671.81% Upside15,872.29% Upside10.56% UpsideNews Sentiment RatingNeutral NewsSee Recent BOLD NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails4/22/2024Piper Sandler2 of 5 stars Initiated CoverageOverweight$20.00+98.22%4/22/2024Guggenheim3 of 5 stars Initiated CoverageBuy$24.00+137.86%4/22/2024Leerink Partners1 of 5 stars Initiated CoverageOutperform$25.00+147.77%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:33 AM ET. BOLD Forecast - Frequently Asked Questions What is Audentes Therapeutics' forecast for 2025? According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Audentes Therapeutics is $23.00, with a high forecast of $25.00 and a low forecast of $20.00. Should I buy or sell Audentes Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BOLD shares. Does Audentes Therapeutics's stock price have much upside? According to analysts, Audentes Therapeutics's stock has a predicted upside of 671.81% based on their 12-month stock forecasts. Do Wall Street analysts like Audentes Therapeutics more than its competitors? Analysts like Audentes Therapeutics more than other "medical" companies. The consensus rating for Audentes Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BOLD compares to other companies. Stock Forecasts and Research Tools Related Companies Abeona Therapeutics Stock Forecast 2seventy bio Stock Forecast Heron Therapeutics Stock Forecast Nektar Therapeutics Stock Forecast ADC Therapeutics Stock Forecast Rigel Pharmaceuticals Stock Forecast Mersana Therapeutics Stock Forecast Acrivon Therapeutics Stock Forecast MacroGenics Stock Forecast Omeros Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here This page (NASDAQ:BOLD) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
